• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8344493).
  

PubMed=6243721; DOI=10.1093/jnci/64.3.465
Magrath I.T., Pizzo P.A., Whang-Peng J., Douglass E.C., Alabaster O., Gerber P., Freeman C.B., Novikovs L.
Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. I Physical, cytogenetic, and growth characteristics.
J. Natl. Cancer Inst. 64:465-476(1980)

PubMed=6243722; DOI=10.1093/jnci/64.3.477
Magrath I.T., Freeman C.B., Pizzo P.A., Gadek J., Jaffe E.S., Santaella M., Hammer C., Frank M.M., Reaman G., Novikovs L.
Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen II. Surface markers.
J. Natl. Cancer Inst. 64:477-483(1980)

PubMed=6265077
Pizzo P.A., Chattopadhyay S.K., Magrath I.T., Del Giacco E., Sherrick D., Gray T.E.
Examination of Epstein-Barr virus and C-type proviral sequences in American and African lymphomas and derivative cell lines.
Cancer Res. 41:3165-3171(1981)

PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493
Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R., Magrath I.T.
Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.
FASEB J. 7:951-956(1993)

PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418
Jain V.K., Judde J.-G., Max E.E., Magrath I.T.
Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
J. Immunol. 150:5418-5428(1993)